Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

CtDNA NGS testing identified a high-level MET amplification (copy number of 53.6 in circulation) (Figure 1A). The test was repeated on a second tube of.

Advertisements

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 The heterogenous landscape of triple-negative breast cancer

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

Figure 1 Key elements of cancer-related inflammation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 3 Risk-adapted and response-adapted

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Generations of cancer vaccine antigens

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 2 Examples of histopathological validation

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Schema for the phase II Randomized Observation versus

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 A schematic representation of the role

chemotherapy for patients with MC versus those with AC

to the liver and promote patient-derived xenograft tumour growth

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 2 The patterns of epithelial-to-mesenchymal

Figure 1 Translocations involved in multiple myeloma

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Frequency and overlap of alterations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Proposed model of clonal evolution in multiple myeloma

Figure 3 Tumours secrete factors that cause systemic immunosuppression

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Integrated mRNA and microRNA expression and DNA methylation clusters.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Gene-expression quantification methods

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.14 Figure 2 Body fluids as a source of tumour-derived molecular information Figure 2 | Body fluids as a source of tumour-derived molecular information. Schematic representation of different body fluids (other than blood) that can contain tumour-derived molecular information, specifically, urine, cerebrospinal fluid (CSF), saliva, and pleural effusions. The localization of the primary tumour and of any metastatic lesions influences the presence of circulating tumour-derived nucleic acids, cells, and microvesicles in individual body fluids. As indicated, point mutations, gene fusions, and methylation changes associated with the cancer can be detected through analysis of DNA or mRNA derived from these blood-borne tumour materials. CTCs, circulating tumour cells; ctDNA, circulating cell-free tumour DNA; miRNA, microRNA. Siravegna, G. et al. (2017) Integrating liquid biopsies into the management of cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.14